Gérard Lledo - Concepedia

Author

Gérard Lledo

Sorbonne Université

Also Known As

B Landi, G Lledo, G Lledó, G Llédo, G. Lledo, Gema M Lledo, Gerard Lledo, Gérard LLEDO, Gérard Lledo, Gérard Lledo

225

Publications

9.4K

Citations

H-Index

Concepts

All Affiliations

Sorbonne Université Hôpital Saint-Antoine Hôpital Tenon Hôpital Privé Jean Mermo Clinique Saint Jean

About

Gérard Lledo is an author at Sorbonne Université specializing in oncology, radiation oncology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	33	1.3K
2	Health Sciences	15	18	720
3	Gastroenterology	4	4	108
4	Hepatology	2	2	33
5	Immunology	2	2	84

Gérard Lledo

Publications

9.2K

Citations

H-Index

Page 1

	Year	Citations
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Christophe Tournigand, Thierry André, Emmanuel Achille, Journal of Clinical Oncology	2003	2.9K
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial Christophe Louvet, Roberto Labianca, Pascal Hammel, Journal of Clinical Oncology	2005	948
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study Christophe Tournigand, Andrés Cervantes, Arié Figer, Journal of Clinical Oncology	2006	799
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2 Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade, Journal of Clinical Oncology	2010	747
Clinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade, Journal of Clinical Oncology	2012	421
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Gérard Lledo, Journal of Clinical Oncology	2009	394
Adjuvant Therapy With Fluorouracil and Oxaliplatin in Stage II and Elderly Patients (between ages 70 and 75 years) With Colon Cancer: Subgroup Analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer Trial Christophe Tournigand, Thierry André, Franck Bonnetain, Journal of Clinical Oncology	2012	385
Randomized Multicenter Phase II Trial of a Biweekly Regimen of Fluorouracil and Leucovorin (LV5FU2), LV5FU2 Plus Cisplatin, or LV5FU2 Plus Irinotecan in Patients With Previously Untreated Metastatic Gastric Cancer: A Fédération Francophone de Cancérologie Digestive Group Study—FFCD 9803 Olivier Bouché, Jean‐Luc Raoul, Franck Bonnetain, Journal of Clinical Oncology	2004	278
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study Christophe Tournigand, Thierry André, Emmanuel Achille, Journal of Clinical Oncology	2023	188
Capecitabine plus oxaliplatin (XELOX) <i>versus</i> 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer Michel Ducreux, Jaafar Bennouna, Mohamed Hebbar, International Journal of Cancer	2010	164

Page 1